Certain spiro-pyrrolidines

ABSTRACT

The present invention concerns new heterocyclic compounds of the formula:   WHEREIN R1 and R2 are inter alia alkyl, chlorine or methoxy, R3 is hydroxy, alkylcarboxy or monoalkylcarbamoyloxy, and A is protected or unprotected carbonyl. The compounds possess analgesic and central nervous system depressant properties.

United States Patent [191 Bastian et al.

[ Aug. 26, 1975 CERTAIN SPlRO-PYRROLIDINES [75] Inventors: Jean-Michel Bastian, Therwil; Klaus Hasspacher, Riehen; Michael Strasser, Basel. all of Switzerland [73] Assignee: Sandoz Ltd., Basel, Switzerland [22] Filed: Nov. 28, 1973 [21] Applr No.: 419,670

Related 1.8. Application Data [63] Continuation-impart of Ser. No. 282,609, Aug. 21,

1972. abandoned.

[30] Foreign Application Priority Data Aug. 23, 197] Switzerland l23l8/7l Nov. 28, 1972 Switzerland 17291/72 [52] U.S. Cl. l 260/326.38; 260/326.45; 260/3265 D; 260/3265 1:260/3265 N;

260/465 D; 260/475 SC; 424/274 [51] Int. Cl. CO7D 205/00 (58] Field of Search 260/3265 J, 326.5 D, 260/3265 B, 326.38

[56] References Cited UNITED STATES PATENTS 3,534,054 l0/l970 Porter .4 260/295 Primary Examiner-Richard J. Gallagher Attorney, Agent, or FirmGerald D. Sharkin; Robert S. Honor 5 7 ABSTRACT The present invention concerns new heterocyclic compounds of the formula:

monoalkylcarbamoyloxy, and A is protected or unprotected carbonyl.

The compounds possess analgesic and central nervous system depressant properties.

72 Claims, No Drawings CERTAIN SPIRO-PYRROLIDINES This application is a continuation-in-part of our copending application Ser. No. 282,609 filed Aug. 21. 1972 now abandoned.

The present invention relates to new heterocyclic compounds.

The present invention provides compounds of forwherein R, is hydrogen, alkyl of l to 3 carbon atoms,

fluorine, chlorine, bromine or methoxy,

R, is hydrogen, alkyl of l to 3 carbon atoms, chlorine or methoxy, or

R, and R are ortho one to another and together form a methylene dioxy group,

R is hydroxy, alkylcarboxy of 2 to 5 carbon atoms or monoalkylcarbamoyloxy of 2 to 5 carbon atoms, and

A is carbonyl, l,3-dioxolan-2-ylidene or 1,3-dioxan- 2-ylidene.

The present invention also provides a process for producing a compound of formula I, comprising a. reacting a compound of formula ll,

ii i

wherein R R and R are as defined above, with a compound of formula [I],

I I I wherein X is chlorine, bromine, iodine or an organic sulphonic acid radical, and A is as defined above and which when carbonyl, may

be protected by ketal, thioxo or thioketal formation, and when required removing any carbonyl protecting groups from the resulting compound, or b. reacting a compound of formula la,

wherein R,, R and A are as defined above, with a compound of formula lVa,

XCOR, lVu

wherein R, is lower alkyl, and

X is chlorine, bromine or the acid radical of a carboxylic acid of l to 4 carbon atoms, to produce a compound of formula lb,

wherein R R R, and A are as defined above, or c. reacting a compound of formula la with a compound of formula lVb,

OCNR, IVh

wherein R, is as defined above, to produce a compound of formula lc,

(on A wherein R,, R- R, and A are as defined above.

Process (a) may, for example, be efi'ected by heating a compound of formula II with a compound of formula III in an inert organic solvent, e.g. an aromatic hydrocarbon such as benzene or toluene, a halogenated hydrocarbon such as chloroform, a cyclic other such as tetrahydrofuran or dioxane, an alcohol such as ethanol, dimethyl formamide or acetone, to a temperature between preferably 50 and 150C, conveniently, with the addition of an acid-binding agent, e.g. an alkali metal carbonate such as sodium or potassium carbonate, or an organic base, e.g. pyridine or triethylamine. The reaction time may range between and hours. Suitable protective groups for the carbonyl function are,

e.g., ketals which are capable of being removed at lower temperatures, preferably at a temperature of below 25C, without the use of highly concentrated acids, such as optionally mixed .ketals of suitable monoor divalent alkyl alcohols, alkylthio alcohols or mixed alkyloxothio alcohols. It is preferred to use cyclic ketals having 5 or 6 ring members, especially dioxolane. The removal of the protective radical from the resulting compound after the reaction is complete, is effected in known manner, e.g. in the case of ketals by hydrolysis with a dilute mineral acid, e.g. with approximately 2 N hydrochloric acid, preferably at a temperature between 0 and approximately 25C. Thioketals may be removed in known manner with mercury (ll) chloride.

Process (b) may be effected in accordance with the usual methods for esterification, e.g. a compound of formula la may be reacted with an acid anhydride or halide of formula lVa, optionally in an inert organic solvent, e.g. an aromatic hydrocarbon such as benzene or toluene, or a cyclic ether such as dioxane, optionally with the addition of an acid-binding agent, e.g. an alkali metal bicarbonate or carbonate such as sodium bicarbonate, sodium carbonate or potassium carbonate, or an organic base such as pyridine or triethylamine, which may simultaneously serve as solvent, at a temperature between approximately 10 and 80C. The reaction time may amount to l to hours.

The production of a compound of formula lc in accordance with process (c) may, for example, be ef fected by reacting a compound of formula la with an alkyl isocyanate of formula IVb, in an inert organic solvent, e.g. an aromatic hydrocarbon such as benzene or toluene, a halogenated hydrocarbon such as methylene chloride or chloroform, or a cyclic ether such as dioxane or tetrahydrofuran, for l to 50 hours at a tempera ture between approximately 10 and 80C.

The compounds of formula. I exist in free base and acid addition salt form. Acid addition salt forms may be produced from free base forms in manner known per se, e.g. by reaction thereof with a suitable acid, and

vice versa.

The compounds of formula I also exist in isomeric forms since they possess two asymmetric centres at position l and 3 of the indan nucleus. Thus, for example, they may be isolated as the lRS,3RS or the lRS,3SR racemates. Such forms are embraced with the scope of formula I. Diastereoisomers may be separated from mixtures thereof in manner known per se, e.g. by fractional crystallization of suitable acid addition salt forms or by chromatography.

Furthermore, the processes (a), (b) and (c) of the invention are stereospecific in the sense that the configuration at the asymmetric centres at positions 1 and 3 of the indan nucleus of the starting materials remains intact and is not affected under the reaction conditions. As will be readily appreciated therefore, when final compounds of particular isomeric form are required, either separation of the final compounds obtained may be effected, or alternatively, starting materials of the desired isomeric forms may be employed.

The starting materials may, for example, be obtained as follows:

a. A compound of formula II may, for example, be obtained by hydrogenolytic debenzylation of a compound of formula V,

wherein R R and R are as defined above. Hydrogenation may, for example, be effected in the presence of a catalyst, preferably a palladium catalyst, in an inert organic solvent, e.g. ethyl acetate or a suit able alcohol such as ethanol.

b. A compound of formula lla,

Ila

wherein R and R are as defined above, may, for example, be obtained by reducing a compound of formula VI,

wherein R, and R are as defined above.

Reduction may, for example, be effected with a complex metal hydride, e.g. lithium aluminium hydride, in an inert organic solvent, e.g. an aromatic hydrocarbon such as benzene, or an ether such as tetrahydrofuran, dioxane, diethyl ether or dimethoxyethane. The reduction may be effected in two stages. Thus for example a compound of formula VI may first be reduced, e.g. with sodium borohydride in a suitable alcohol such as methanol, or an alcohol/water mixture, or hydrogenolytically in the presence of a catalyst, e.g. platinum oxide, conveniently in a suitable alcohol, to obtain a compound of formula Vla,

VIa.

wherein R, and R are as defined above, and this may then be further reduced, e.g. with lithium aluminium hydride, to obtain a compound of formula Ila.

The above reductions may proceed with some stereochemical control such that the production of one diastereoisomeric form of the compounds of formula Vla or lla, predominates depending on the nature of substituents R and R and the reduction conditions used, i.e. the reactions may, in some circumstances, be said to involve asymmetric induction. When mixtures of diastereoisomeric forms are obtained, they may be separated in known manner, eg. by fractional crystallization or by chromatography.

c. A compound of formula Vb,

wherein R,, R and R, are as defined above, may, for example, be obtained by reacting a compound of formula Va,

wherein R, and R are as defined above, with a compound of formula lVa, as described in process (b). d. A compound of formula Vc,

iw-coaia-a wherein R,, R and R, are as defined above, may, for example, be obtained by reacting a compound of formula Va, as described in process (e with a com pound of formula lVh.

e'. A compound of formula Va may, for example. be obtained by reducing a compound of formula Vll,

VII

wherein R, and R are as defined above, as described in process (b' f. A compound of formula VI! may, for example, be obtained by benzylating a compound of formula VI with a compound of formula Vlll,

VIII

wherein R and R are as defined above, with polyphosphoric acid. Cyclization is optionally effected in an inert organic solvent, e.g. an aromatic hy drocarbon such as benzene, at a temperature between and C. h. A compound of formula IX may, for example, be obtained by hydrolysis of a compound of formula X,

wherein R and R are as defined above, and R is lower alkyl. Hydrolysis is preferably effected in an alkaline medium. i. A compound of formula X may, for example, be ob tained by hydrogenating a compound of formula Xl,

- c--CN -COOR CH --CIl wherein R R and R are as defined above, in conventional manner with a bromoacetic acid alkyl ester in the presence of a basic condensation agent. k. A compound of formula XII may be obtained by reacting a compound of formula XIII,

C cooa CH x111 wherein R R and R are as defined above, optionally in the presence of a water-miscible inert organic solvent, e.g. a suitable alcohol of formula XIV,

XIV

wherein R is as defined above, with an aqueous alkali metal cyanide solution. The reaction is preferably effected at an elevated temperature, eg at a temperature between 40 and 100C, and may have a duration between and hours. I'. A compound of formula XIII may, for example. be obtained by reacting a compound of formula XV,

R i/HCHO wherein R and R are as defined above, with a malonic acid ester of formula XVI.

COORr H XVI wherein R is as defined above, in conventional manner.

Insofar as the production of the starting materials is not particularly described, these are known or may be produced in accordance with known processes. or in a manner analogous to the processes described herein or to known processes.

The compounds of formula I are useful because they possess pharmacological activity in animals. In particular the compounds are useful as analgesics, as indicated by standard tests, for example, in the tail flick test in mice at a dose of approximately l to 30 mg/kg animal body weight s.c., and by an inhibition of the phenyl benzoquinone syndrome in mice at a dose of approximately 1.5 to 30 mg/kg animal body weight p.o.

For the abovementioned use, the dosage to be administered will of course vary depending on the compound employed, mode of administration and treatment desired. However, in general, satisfactory results are ob tained when administered at a daily dosage of from about 1 to 30 mg/kg animal body weight, orally or parenterally, preferably given in divided doses 2 to 4 times daily or in sustained release form. For the larger mammals the total daily dosage is in the range of from about 50 to 500 mg, and dosage forms suitable for oral administration contain from about 12 to 250 mg of the compound admixed with a solid or liquid pharmaceutical carrier or diluent. p-Fluoro-4-( 3- hydroxyspiro[ indan-l ,3 -pyrrolidin ]-l 'yl) butyrophenone has been found to be particularly effective as an analgesic when administered p.o. generally at a dosage of from about 5 to 10 mg/kg animal body weight.

The compounds are furthermore useful as central nervous system depressants, particularly for sedation in the treatment of excitation conditions and sleep disorders, as indicated by standard tests, for example, in the climbing test with mice at a dose of approximately 3 to 30 mg/kg animal body weight, and in the light barrier cage test in mice, to determine the motor activity of the mice, at a dose of approximately 3 to 30 mg/kg animal body weight. The compounds also produce a lowering of rectal temperature in mice at a dose of approximately 30 to 50 mg/kg animal body weight, an effect consistent with compounds having a central nervous system depressant effect.

For the abovementioned further use, the dosage administered will, of course vary depending on the compound employed, mode of administration and treatment desired. However, in general, satisfactory results are obtained when administered at a daily dosage of from about I to 50 mg/kg animal body weight, orally or parenterally, preferably given in divided doses 2 to 4 times daily or in sustained release form. For the larger mammals, the total daily dosage is in the range of from about 50 to 500 mg, and dosage forms suitable for oral administration contain l2 to 250 mg of the compound in admixture with a solid or liquid pharmaceutical carrier or diluent. 4-( S-Chloro-3-hydroxyspiro[ indanl ,3 pyrrolidin l-l yl J-p-fluorobutyrophenone has been found to be particularly effective in the treatment of excitation conditions and sleep disorders when administered p.o. at a dosage generally of l2.5 mg/kg animal body weight.

The compounds of formula I in free base or pharmaceutically acceptable acid addition salt form may be incorporated in a pharmaceutical composition in association with pharmaceutical carriers or diluents. Suitable forms of composition for oral administration are a tablet and a capsule.

One preferred group of compounds are the compounds of formula I wherein R, and R, are hydrogen.

When R and R, are other than hydrogen, then one of the substitucnts is preferably in the 5 position of the indan nucleus.

R in formula 1 is preferably methylcarboxy or methylcarbamoyloxy.

Free base and pharmaceutically acceptable acid addition salt forms of the compounds of the invention exhibit the same order of activity. Examples of pharmaceutically acceptable acid addition salt forms are the hydrochloride. hydrobromide, sulphate, hydrogen fumarate, malonate and naphthalene-l,S-disulphonate.

The invention is illustrated with reference to the following Examples, wherein all temperatures are indicated in degrees Centigrade. Unless otherwise indicated, the title compounds in the Examples are obtained as a mixture of diastereoisomeric forms.

EXAMPLE I p-Fluoro-4-( 3-hydroxyspiro[ indanl ,3 -pyrrolidin l '-yl) butyrophenone A. g of spirolindan-l,3-pyrrolidin]-3-ol are dis solved in 200 cc of dimethyl formamide, and the solution is heated to 100 with 18 g of sodium carbonate and 23 g of 2-(3-chloropropyl)-2-(p-fiuorophenyl)- l,3'-dioxolane for hours. Filtration is subsequently effected, the filter residue is washed with 150 cc of chloroform, and the organic phases are concentrated. The 2-[ 3-( 3-hydroxyspiro[indanl ,3 '-pyrrolidin l yl )propyl ]-2-( p-fluorophenyhl ,3-dioxolane obtained as yellow oil is taken up in 300 cc of chloroform without previous purification and is stirred with 250 cc of 2 N hydrochloric acid at room temperature for 1% hours. The reaction mixture is subsequently rendered alkaline with caustic soda solution. is extracted thrice with I00 cc amounts of chloroform, and the chloroform phase is concentrated. The crude title compound is obtained as brown oil, to which a solution of 8 g of fumaric acid in 150 cc of ethanol is added. After the addition of some ether, the hydrogenfumarate of the title compound is obtained. M.P. l74l76 (from ethanol/ether).

B. 8.5 g of spiro[indan-l,3'-pyrrolidin]-3-ol, 12.0 g of 4'chloro-p-fluorobutyrophenone and 11.5 g of sodium carbonate are heated at reflux in I00 cc of dimcthyl formamide while stirring for 20 hours. After cooling, filtration is effected. the filtrate is evaporated to dryness, taken up in 300 cc of chloroform and extracted thrice with 50 cc amounts of 2 N hydrochloric acid. The acid extract is rendered alkaline with 2 N caustic soda solution while cooling and extraction is effected with chloroform. The crude title compound, obtained as oil after concentrating the chloroform phase by evaporation. is converted into the hydrogen fumarate with fumaric acid. The hydrogen fumarate of the title compound has a MP. of l74l76 (from ethanol/ether).

C. lRS, 3SR-p-Fluoro-4-( 3-hydroxyspiro[ indanl ,3

pyrrolidin1-l -yl) butyrophenone Nuclear magnetic resonance measurements with the use of an europium complex indicate that the hydrogen fumarate of the title compound obtained in accordance with Example 1 (A) or l (B), having a M.P. of

l74-l 76, is a mixture of diastereoisomers, which contains 30 of the lRS,3RS isomer. and of the IRS,3SR isomer. l2 g of this mixture are dissolved in ethanol, and a small amount of ether is added. The compound which crystallizes slowly is sterically pure, as indicated by its nuclear magnetic resonance spectrum, and is the hydrogen fumarate of lRS,3SR-pfluoro-4-( 3-hydroxyspiro[ indanl ,3 '-pyrrolidin l -yl) butyrophenone, having a M.P. of 183.

D. 1RS,3RS-p-Fluoro-4-( 3-hydroxyspiro[ indanl ,3

pyrrolidin1-l -yl butyrophenone The mother liquor obtained in Example I (C) is concentrated, 50 cc of chloroform are added to the residue and this is shaken thoroughly with 50 cc of a 2 N caustic soda solution. The crude lRS,3RS-p-fluoro-4-(3- hydroxyspiro[ indanl ,3 '-pyrrolidin]-l '-yl) butyrophenone, obtained after concentrating the chloroform phase which has been washed and dried over magnesium sulphate, is purified by chromatography on silica gel, and 20 cc of ethanol saturated with hydrogen chloride gas are added. After the addition of some ether, the hydrochloride of the lRS,3RS isomer, having a M.P. of 2l021 1, crystallizes.

The starting material may be produced as follows a. 200 g of malonic acid diethyl ester, [44 g of benzaldehyde, 14 cc of piperidine and ll.7 g of benzoic acid are heated in 400 cc of benzene for 14 hours at water separating reflux (bath temperature l30-l40, water separation about 25 cc). After cooling, 200 cc of benzene are added and washing is successively effected twice with 200 cc amounts of water, twice with 200 cc amounts of l N hydrochloric acid and I00 cc of a saturated sodium bicarbonate solution, and the benzene is removed by distillation on a rotary evaporator. The resulting benzalmalonic acid diethyl ester is purified by distillation. B.P. l43l52/0.2 mm Hg, B.P. l27-l34/0.l mm Hg.

b. l20 g of benzalmalonic acid diethyl ester, 33.6 g of potassium cyanide, 1600 cc of ethanol and cc of water are stirred at a bath temperature of 60 for 12 to 14 hours. The reaction mixture is then cooled with ice water, the potassium bicarbonate which crystallizes is filtered off, the filtrate is made neutral with about l5 cc of l N hydrochloric acid, air is passed through the solution with a water jet vacuum pump for l hour, the solvent is distilled off on a rotary evaporator, I00 cc of water are added to the oily residue, and extraction is effected 6 times with 250 cc amounts of ether. The 3-cyano-3-phenylpropionic acid ethyl ester, obtained after distilling off the ether, is purified by vacuum distillation. B.P. l25-l30/0. l5 mm Hg.

c. 42 g of sodium amide suspended in 400 cc of absolute ether are added dropwise at room temperature to a solution of I58 g of 3-cyano-3-phenylpropionic acid ethyl ester and 144 g of bromoacetic acid ethyl ester in 1 litre of absolute ether. After adding about half of the suspension, the reaction solution has a light brown colour and starts to boil. After the dropwise addition is complete. the reaction solution is heated at reflux for 2 hours, is cooled, the excess sodium amide is decomposed by the careful dropwise addition of water, the ether solution is washed with 250 cc of 2 N hydrochloric acid and 250 cc of water and is concentrated by evaporation. The resulting 3-cyano-3-phenylglutaric acid diethyl ester is purified by vacuum distillation. B.P. l72l75/0.08 mm Hg.

d. 45 g of Raney nickel are added to 254.2 g of -cyano-3-phenylglutaric acid diethyl ester in 1.5 litres If absolute methanol, and hydrogenation is effected in 5 litre autoclave for 30 hours at 80 and a hydrogen Iressure of 81 atmospheres. After cooling, the catalyst filtered off, the filtrate is concentrated on a rotary vaporator, the resulting light yellow oil is taken up in .5 litres of chloroform and is successively washed with .5 cc of 2 N hydrochloric acid, 100 cc of saturated solium bicarbonate solution and 100 cc of water. The -oxo-3-phenyl-3-pyrrolidine acetic acid ethyl ester, Ibtained after concentrating the chloroform phase. rystallizes upon triturating with ether. M.P. 49-51 from ethyl acetate/petroleum ether).

e. 195 g of 5-oxo 3 phenyl-3-pyrrolidine acetic acid thyl ester are dissolved in a mixture of 200 cc of water, -7 g of sodium hydroxide and 750 cc of ethanol while tirring at room temperature. After allowing to stand at oom temperature for 1 hour, the sodium salt of -oxo-3-phenyl-3-pyrrolidine acetic acid crystallizes. It dissolved in 600 cc of water and acidified with about I cc of 2 N hydrochloric acid while cooling with ice, whereby -oxo-3-phenyl-3-pyrrolidine acetic acid sep- .rates in crystalline form. M.P. 186l88 (from ethalOl).

f. 200 g of polyphosphoric acid are heated to 160; 30 g of 5-oxo-3-phenyl3-pyrrolidine acetic acid are apidly added while stirring, and the mixture is kept at his temperature for 5 minutes. The mixture is then :ooled and poured on 800 g of ice, is extracted l0 imes with 150 cc amounts chloroform, and the chloro orm phase is concentrated in a vacuum. The resulting pirol indanl ,3 '-pyrrolidin]-3,5 '-dione which becomes :rystalline upon triturating and seeding, is recrystalized from 70 to 80 cc of ethanol. M.P. l52-l53.

g. 17.1 g of lithium aluminium hydride in 300 cc of lbsolute tetrahydrofuran and 600 cc of absolute benene are placed in a Soxhlet apparatus. 30 g of the spirrlindan-l,3'-pyrrolidin]-3,5'-dione to be reduced are alaced in the Soxhlet apparatus in a Soxhlet capsule. ioiling at reflux is then effected for 20 hours, whereby he entire product is dissolved. The reaction mixture is ubsequently cooled and carefully decomposed with 25 :c of water in 25 cc of tetrahydrofuran, the precipitate s filtered off and the filtrate concentrated. Spiro[inda- |-l,3'-pyrrolidin]-3-ol is obtained as light yellow oil md is converted into its hydrogen fumarate by reacting vith a solution of 17 g of fumaric acid in 400 cc of etha- IOl. M.P. l55-l58 (from ethanol/ether).

EXAMPLE 2: p-Fluoro-4-( 3'hydroxy-o-methoxyspirol indanl ,3

pyrrolidin ]-l '-yl) butyrophenone A. g of 6-methoxyspiro[indan1,3'-pyrrolidin]-3- )1 (mixture of diastereoisomers) and 15 g of 4-chloroi'fluorobutyrophenone are heated to the boil in 300 cc If absolute toluene. 22 g of sodium carbonate are ldded in small portions within 30 minutes, and a furher 10 g of sodium carbonate are added after hours, ind the mixture is boiled at reflux for a total of 30 IOUI'S. After cooling filtration is effected. the filter resilue is boiled with chloroform, and the combined organic phases are concentrated by evaporation. The reulting crude, light brown, oily title compound is con- 'erted into the hydrogen fumarate with fumaric acid. l'he hydrogen fumarate of the title compound (mixture of diastereoisomers 35:65) has a M.P. of 163l65 (from ethanol/ether).

B. 15 g of o-methoxyspirolindan-l,3'-pyrrolidin]3- 01 and 22 g of 2-(3-chloropropyl)-2-(p-fluorophenyl)- l ,3'-dioxolane are reacted in accordance with the process described in Example 1 A). The hydrogen fumarate of the title compound has a M.P. of l63-l65 (from ethanol/ether).

The starting material may be produced as follows:

a. m-Methoxybenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example a). B.P. l4()l50/0.05 mm Hg, M.P. 45.

b. 3-Cyano-3-(m-methoxyphenyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example 1 b). B.P. l40l50/0.3 mm Hg.

0. 3-Cyano-3-(m-methoxyphenyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example 1 0). RP. l63l68/0.2 mm Hg.

d. 3-(m-Methoxyphenyl)-5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example I d). The crude compound obtained as viscous oil is used for the next reaction without purification.

e. 3-(m-Methoxyphenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 1 e). The alkaline reaction solution is shaken thoroughly once with cc of methylene chloride in order to remove the byproducts of hydrogenation. Extraction is then effected once with 750 cc of 2 N hydrochloric acid and 5 times with 150 cc amounts of methylene chloride, the methylene chloride phases are concentrated and the resulting compound is recrystallized from ethanol. M.P. l44l46.

f. 3-(m-Methoxyphenyl)-5-oxo-3-pyrrolidine acetic acid is reacted in a manner analogous to that described in Example 1 f). The resulting yellow, oily crude product is a mixture of isomers of 6-methoxyspiro [indanl,3'-pyrrolidin]-3,5 '-dione and 4-methoxyspiro[indanl,3'-pyrrolidin]-3,5'-dione. Upon adding about 20 cc of ethanol, 6 methoxyspiro[ indan-l ,3 pyrrolidin 3,5'-dione crystallizes in the form of white crystals.-

g. -Methoxyspirolindanl ,3'-pyrrolidin ]-3-o1, produced in a manner analogous to that described in Example g), from 6-methoxyspiro[indan-1,3- pyrrolidin ]-3,5 '-dione. M.P. 1 38 (from ethanol/ether).

EXAMPLE 3:

4-( 6-Chloro-3-hydroxyspiro[ indanl ,3 '-pyrrolidin ]-1 yl )-p-fl uorobutyrophenone o-Chlorospirolindanl ,3'-pyrrolidin l-3-ol (mixture of diastereoisomers) is reacted in a manner analogous to that described in Example 1 (A) or Example 2 (A). The crude, light brown oily title compound is purified by chromatography on silica gel and is subsequently converted into the hydrogen fumarate. The hydrogen fumarate of the title compound (mixture of diastereoisomers) has a M.P. of l65l67 (from methanol/ether).

The starting material may be obtained as follows:

a. m-Chlorobenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example l (a). SP. l38l39/0.3 mm Hg.

b. 3-( m-Chlorophenyl)-3-cyanopropionic acid ethyl ester, produced in a manner analogous to that described in Example I b). 8.1. l58l62/0.5 mm Hg.

c. 3-(m-Chlorophenyl)-3-cyanoglutaric acid diethyl ester, produced in a manner analogous to that described in Example 1 c). B.P. l66-l7ll().4 mm Hg.

d. 3-(m-Chlorophenyl)5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l d). The crude product is used for the next reaction without purification.

e. 3-(m-Chlorophenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2 e). M.P. l78l8l.

f. 3-(m-Chlorophenyl)-5-oxo-3-pyrrolidine acetic acid is reacted in a manner analogous to that described in Example l f). Reaction time 15 minutes. The reaction mixture is extracted with methylene chloride. The crystalline product obtained after concentrating the methylene chloride phase by evaporation, is a mixture of isomers of 6-chlorospiro[indan-l ,3-pyrrolidin]- 3,5 '-dione and 4-chlorospiro[indan-l ,3'-pyrrolidin]- 3,5 '-dione. The two isomers are separated by fractional crystallization from methylene chloride/ethanol. 6- Chlorospirol indanl ,3 '-pyrrolidin ]-3,5 '-dione has a M.P. of 2 l 220. 4-Chlorospiro[ indanl ,3 pyrrolidin]-3,5'-dione has a M.P. of l76l79.

g. 25 g of 6-chlorospiro[indan-l,3'-pyrrolidin]-3,5- dione are dissolved in 100 cc of dimethyl formamide and 250 cc of methanol, and a suspension of 2 g of sodium borohydride in 50 cc of water and 5 drops of caustic soda solution are added dropwise at room temperature. The temperature is kept at by cooling. The solution is stirred for an hour at room temperature, is then poured on water and extracted several times with chloroform. The mixture of the diastereoisomeric forms of 6-chloro-3-hydroxy[indan-l,3-pyrrolidin]- 5'-one, obtained after concentrating the chloroform phase by evaporation, is used as such for the next reaction.

h. A solution of 25 g of 6-chloro-3- hydroxyspirolindan-l,3"pyrrolidin]5'-one in 100 cc of ether and 100 cc of tetrahydrofuran is added dropwise to a suspension of 8.5 g of lithium aluminium hydride in 200 cc of tetrahydrofuran and 200 cc of ether. The mixture is boiled at reflux for 20 hours, is then carefully decomposed with 75 cc of water, filtration is effected, and the organic phases are concentrated. The resulting yellow oil is a mixture of the diastereoisomeric forms of b-chlorospirol indan-l ,3 pyrrolidin1-3-ol and is used for the next reaction without further purification.

EXAMPLE 4: 44 4-Chloro-3-hydroxyspirol indanl ,3 '-pyrrolidinl-l yl )p-fluorobutyrophenone 4-Chlorospirol indan-l .3 "pyrrolidin 1-3 -ol (mixture of diastereoisomers) is reacted in a manner analogous to that described in Example l(A) or Example 2(A). After purifying the crude product by chromatography on silica gel, the diastereoisomeric forms of the title compound are obtained as oils. After recrystallization from methanol/ether, the hydrogen fumarates of the diastereoisomers of the title compound have a M.P. of l6l-l63 or l9U-l92.

The starting material is obtained from 4- chlorospirolindan-l ,3 -pyrrolidin |-3,5 '-dione [production see Example 3(f)] in a manner analogous to that described in Example 3(g) to 3(h).

EXAMPLE 5: 4-( 5-Chloro-3-hydroxyspiro[ indanl ,3 '-pyrrolidin l yl )-p-fluorobutyrophenone S-Chlorospirolindanl ,3 '-pyrrolidin]-3-ol is reacted in a manner analogous to that described in Example l(A) or Example 2(A). The hydrogen fumarate of the title compound has a M.P. of l48l49.

The starting material may be obtained as follows:

a. p-Chlorobenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example 4(a). B.P. l35l42/0.2 mm Hg.

b. 3-(p-Chlorophenyl)-3-cyanopropionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l4ll45/0.3 mm Hg.

c. 3-(p-Chlorophenyl)-3-cyanoglutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). B.P. 166l69/0.3 mm Hg.

d. 3-(p-Chlorophenyl)-5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The crude product is used as such for the next reaction.

e. 3-(p-Chlorophenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. ll9l.

f. 5-Chlorospiro[indanl ,3 '-pyrrolidin]-3,5 -dione, produced in a manner analogous to that described in Example l(f). M.P. 220222.

g. 5-Chloro-3-hydroxyspirolindan-l ,3 '-pyrrolidin 1- 5-one, produced in a manner analogous to that described in Example 3(g). M.P. 172l74.

h. 5-Chlorospiro[indan-l,3'-pyrrolidin]-3-ol, produced in a manner analogous to that described in Example 3(h). The crude product is used as such for the next reaction.

EXAMPLE 6: p-Fluoro-4-( 3-hydroxy-4-methoxyspirol indan-l ,3

pyrrolidin1-l '-yl) butyrophenone 4-Methoxyspirolindanl ,3 '-pyrrolidin]-3-ol is reacted in a manner analogous to that described in Example l(A) or Example 2(A). The hydrogen fumarate of the title compound has a M.P. of l52154 (from ethanol/ether).

The 4-methoxyspiro[indan-l ,3 '-pyrrolidin ]3-ol, M.P. l84l86, required as starting material, is obtained in a manner analogous to that described in Example 2(g) from 4-methoxyspiro[ indanl ,3 pyrrolidin]-3,5-dione, M.P. l84l86, which is obtained from the mother liquor resulting after crystallizing the 6-methoxyspiro[ indanl ,3 '-pyrrolidin]-3,S dione in Example 2(f).

EXAMPLE 7:

p-Fluoro-4-( 3-hydroxy-6-methylspiro[ indan-l ,3

pyrrolidin1- l -yl) butyrophenone 6-Methylspiro[ indan-l ,3 '-pyrrolidin]-3 ol is reacted in a manner analogous to that described in Example l(A) or Example 2(A). The hydrogen furnarate of the title compound has a M.P. of l72l74 (from ethanol/ether).

The starting material may be obtained as follows:

a. m-Methylbenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example l a). HP. l35-l4(l/().4 mm Hg.

b. 3-Cyano-3-(m-tolyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l43l48/0.l mm Hg.

c. 3-Cyano-3-(m-tolyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). B.P. ]60l67/().08 mm Hg.

d. 5-Oxo-3-(m-to1yl)-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The crude product is used as such for the next reaction.

e. 5-Oxo-3-(m-tolyl)-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. ]52l54.

f. o-Methylspirofindan-l ,3 -pyrrolidin 1-3 ,5 '-dione. produced in a manner analogous to that described in Example l(f). M.P. l88l92.

g. 3-Hydroxy-6-methylspirolindan-l ,3'-pyrrolidin1- 5'-one, produced in a manner analogous to that described in Example 3(g), used for the next reaction as crude product.

h. 6-Methylspiro[ indanl ,3 -pyrrolidin1-3-ol, produced in a manner analogous to that described in Example 3(h). used for the next reaction as crude product.

EXAMPLE 8: p- Fluoro-4-( 5-fluoro-3-hydroxyspiro indan-l ,3 pyrrolidin1-l -yl) butyrophenone 5-Fluorospiro[indan-1,3 -pyrrolidin1-3-ol is reacted in a manner analogous to that described in Example l(A) or Example 2(A). The hydrogen fumarate of the title compound has a M.P. of l43l45 (from ethanol/ether).

The starting material may be obtained as follows:

a. p-Fluorobenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example l(a)t B.P. l49l53/U.9 mm Hg.

b. 3-Cyano-3-(p-fluorophenyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l46l60/O.5 mm Hg.

c. 3-Cyano-3-(p-fluorophenyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). M.P. 687() (from ether/pctroleum ether).

d. 3-(p-Fluorophenyl)-5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The crude compound obtained as a viscous oil is used as such for the next reaction.

e. 3-(p-Fluorophenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. l74l76.

f. 5-Fluorospiro[indan-l,3'-pyrrolidin1-3,5-dione, produced in a manner analogous to that described in Example l(f). M.P. l98--202.

g. S-Fluorospirolindan-l,3'-pyrrolidin1-3-ol, produced in a manner analogous to that described in Example l(g The crude compound is converted into the hydrogen fumarate. M.P. 162 l 64 (from ethanol/ether).

EXAMPLE 9: p-Fluoro-4-( 3-hydroxy-S-methoxyspirol indanl ,3 pyrrolidin ]-l '-yl) butyrophenone S-Methoxyspirol indanl ,3 -pyrrolidin 1-3-ol (mixture of diastereoisomers) is reacted in a manner analogous to that described in Example l(A) or Example 2(A).

The hydrogen fumarate of the title compound (mixture of diastereoisomers :30) has a M.P. of ll3l l5 (from ethanol/ether).

The starting material may be obtained as follows:

a. p-Methoxybenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example l(a). B.P. ]45l60/().5 mm Hg.

b. 3-Cyano-3-(p-methoxyphenyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l2()0/0.3 mm Hg.

c. 3-Cyano-3-(p-methoxyphenylJglutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). M.P 6575 (from ether/petroleum ether).

d. B-(p-Methoxyphenyl)-5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The compound is used in crude state for the next reaction.

e. 3-(p-Methoxyphenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. l72l75.

f. 5-Methoxyspiro[ indanl ,3'-pyrrolidin1-3,5 '-dione, produced in a manner analogous to that described in Example l(f). M.P. l79l8().

g. 5-Methoxyspiro1indan-l,3-pyrrolidin]-3-ol, produced in a manner analogous to that described in Example l(g). The crude compound (mixture of diastereoisomers) is used for the next reaction without purificatron.

EXAMPLE l0: p-Fluoro-4-( 3-hydroxy-5-methylspiro[ indanl ,3 pyrrolidin 1- l 'yl) butyrophenone S-Methylspirolindan-l,3-pyrrolidin]-3-ol (mixture of diastereoisomers) is reacted in a manner analogous to that described in Example l(A) or Example 2(A). The hydrogen fumarate of the title compound (mixture of diastereoisomers 25:75) has a M.P. of l63l64 (from ethanol/ether).

The starting material may be obtained as follows:

a. p-Methylbenzalmalonic acid ethyl ester, produced in a manner analogous to that described in Example l(a). B.P. l60l67/O4 mm Hg.

b. 3-Cyano-3-(p-tolyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example ](b). B.P. l45l55/().3 mm Hg.

c. 3-Cyano-3-(p-tolyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). B.P. l8Sl90/U.S mm Hg.

d. 5-Oxo-3-(p-tolyl)-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The compound is used in crude state for the next reaction.

e. 5-Oxo-3-(p-tolyl)-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(c). M.P. l84l86.

f. S-Methylspiroi indan-l ,3'-pyrrolidin1-3.S'-dione, produced in a manner analogous to that described in Example l(f). M.P. l(12l64.

g. S-Methylspirol indanl ,3 '-pyrrolidin 1-3-01, produced in a manner analogous to that described in Example l(g). The compound (mixture of diastereoisomers) is used in crude state for the next reaction.

EXAMPLE I l 4-(5,7-Dichloro-3-hydroxyspirolindan-1.3- pyrrolidin 1-1 '-yl ).-,p-iluorobutyrophenone 5,7-Dichlorospirol indanl ,3 '-pyrrolidin l-3-ol is reacted in a manner analogous to that described in Example l(A) or Example 2(A). The hydrogen fumarate of the title compound has a MP. of l49-l52 (from ethanol/ether v The starting material may be obtained as follows:

a. 2,4-Dichlorobenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example l(a). B.P. l72l78/0.4 mm Hg.

b. 3-(2,4-Dichlorophenyl)-3-cyanopropionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l80-l85/0.5 mm Hg.

c. 3-(2,4-Dichlorophenyll-3 cyanoglutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). The compound is used in crude state for the next reaction.

d. 3-( 2,4-Dichlorophenyl )--oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The compound is used in crude state for the next reaction.

e. 3-( 2,4-Dichlorophenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. l88" -192 (from ethanol/ether).

i. 5 ,7-Dichlorospiro[ indan-l ,3 '-pyrrolidin ]-3,5 dione, produced in a manner analogous to that described in Example l(f). M.P. 226228.

g. 5 ,7-Dichlorospiro[ indanl ,3 '-pyrrolidin ]-3ol, produced in a manner analogous to that described in Example l(g). Light yellow oil, which is used for the next reaction without purification.

EXAMPLE l2: 4-( 4,5-Dichloro-3hydroxyspiro[ indanl ,3 pyrrolidin1- l '-yl l-p-fluorobutyrophenone 4.5-Dichlorospiro[ indanl ,3 '-pyrrolidin 1-3-01 (mixture of diastereoisomers) is reacted in a manner analogous to that described in Example l(A) or Example 2( A). The hydrogen fumarate of the title compound has a M.P. of l9()-l93.

The starting material may be obtained as follows:

a. 3,4-Dichlorobenzalmalonic acid diethyl ester, produced in a manner analogous to that described in Example l a). B.P. l69l73/0.5 mm Hg.

b. 3-(3,4-Dichlorophenyl)-3-cyanopropionic acid ethyl ester. produced in a manner analogous to that described in Example l(b). B.P. l85l95/().5 mm Hg.

c. 3-(3,4-Dichlorophenyl)3-cyanoglutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). White crystals having a MP. of 6567.

d. 3-( 3 ,4-Dichlorophenyl )-5-oxo-3-pyrrolidine acetic acid ethyl ester. produced in a manner analogous to that described in Example l(d). The crude compound is used for the next reaction without purification.

e. 3-( 3,4-Dichlorophenyl )-5oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. l9l-l95.

f. 4,5-Dichlorospirolindan-1,3 '-pyrrolidin ]-3,5 dione, produced in a manner analogous to that described in Example l(f). The crystalline product obtained after recrystallization from ethanol contains a small amount of impurities of 5,6-dichlorospiroiindan- EXAMPLE l3: 4-( 3-Hydroxy-5.6-dimethoxyspiro[ indanl ,3 pyrrolidin l-l '-yl )-p-fluorobutyrophenone 5,6-Dimethoxyspiro[indanl ,3 -pyrrolidin]-3-ol is reacted in a manner analogous to that described in Example 1(A) or Example 2(A).

A solution of naphthalene-l,S-disulphonic acid in ethanol is added to the crude oily title compound, whereby the naphthalene-l,S-disulphonate of the title compound crystallizes and has a M.P. of l46-l48 after recrystallization from ethanol.

The starting material may be obtained as follows:

a. 3,4-Dimethoxybenzalmalonic acid ethyl ester, produced in a manner analogous to that described in Example l(a). B.P. l-2l0/0.l mm Hg.

b. 3-Cyano-3-(3,4-dimethoxyphenyl)propionic 'acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. 205-212/0.3 mm Hg.

c. 3-Cyano-3-(3,4-dimethoxyphenyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example 1c). B.P. 2l5225/0.l mm Hg.

d. 3-( 3,4-Dimethoxyphenyl)-5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The compound is used for the next reaction in crude state.

e. 3-( 3,4-Dimethoxyphenyl )-5oxo-3- pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. l62-l65.

f. 5,6-Dimethoxyspirolindan-l ,3 '-pyrrolidin]-3,5 dione, produced in a manner analogous to that described in Example l(f). M.P. l93-l95.

g. 5,6-Dimethoxyspiro[indan-l ,3 '-pyrrolidin]-3-ol, produced in a manner analogous to that described in Example l( g). Yellow oil, which is used as such for the next reaction.

In analogous manner to that described in the preceding example, the compound 4-( 3-hydroxy-5,6- methylenedioxyspiro[ indanl ,3 -pyrrolidin]-l '-yl )-pfluoro-butyrophenone may be produced.

EXAMPLE l4: 4-( 3-Hydroxy-5-isopropylspiro[indanl ,3 '-pyrrolidin l '-yl )-p-fluorobutyrophenone 5-lsopropylspiro[indanl ,3'-pyrrolidin ]-3-ol (mixture of diastereoisomers) is reacted in a manner analogous to that described in Example l(A) or Example 2(A), and the title compound is converted into its hydrogen fumarate having a M.P. of 167l74.

The starting material may be obtained as follows:

a. 4-lsopropylbenzalmalonic acid ethyl ester, produced in a manner analogous to that described in Example l(a). B.P. l52l54/0.4 mm Hg.

b. 3-Cyano-3 (4isopropylphenyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l46-l49/0.l mm Hg.

c. 3-Cyano-3-(4-isopropylphenyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). B.P. l6619U/0.2-U.4 mm Hg.

d. 3-(4-lsopropylphenyl)-5-oxo'3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). The compound is used for the next reaction in crude state.

e. 3-(4-lsopropylphenyl)-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. 175-l78.

f. -lsopropylspirol indanl ,3 -pyrrolidin ]-3,5 dione, produced in a manner analogous to that described in Example l(f). M.P. l65l67.

g. 5-lsopropylspirolindan-l,3'-pyrrolidin]-3-ol, produced in a manner analogous to that described in Example l(g). Yellow oil, which is used as such for the next reaction.

EXAMPLE l5: 4-( 3-Hydroxy-5,7-dimethylspirol indanl ,3 pyrrolidin]-1 'yl )-p-fluorobutyrophenone 5,7-Dimethylspiro[ indanl ,3 '-pyrrolidin ]-3-ol is reacted in a manner analogous to that described in Example l(A) or Example 2(A), and the title compound is converted into its hydrogen fumarate having a MP. of l64l67.

The starting material may be obtained as follows:

a. 2,4-Dimethylbenzalmalonic acid ethyl ester, produced in a manner analogous to that described in Example l(a). B.P. l3814l/().l5 mm Hg.

b. 3-Cyano-3-(2,4-dimethylphenyl)propionic acid ethyl ester, produced in a manner analogous to that described in Example l(b). B.P. l4()l50/0.25().35 mm Hg.

c. 3-Cyano-3-(2,4-dimethylphenyl)glutaric acid diethyl ester, produced in a manner analogous to that described in Example l(c). B.P. l80l90/0.l5 mm Hg.

(1. 3 2,4-Dimethylphenyl )-5-oxo-3-pyrrolidine acetic acid ethyl ester, produced in a manner analogous to that described in Example l(d). ls used for the next reaction in crude state.

e. 3-( 2,4-Dimethylphenyl )-5-oxo-3-pyrrolidine acetic acid, produced in a manner analogous to that described in Example 2(e). M.P. 225-23().

f. 5,7-Dimethylspiro[ indanl ,3 '-pyrrolidin ]-3,5 dione, produced in a manner analogous to that described in Example l(f). M.P. 2082l0.

g. 5 ,7-Dimethylspiro[ indan l ,3 '-pyrrolidin ]-3-ol, Jroduced in a manner analogous to that described in Example l(g). Yellow oil, which is used as such for the text reaction.

EXAMPLE l6: lRS,3 RS-p-Fluoro-4-( 3-hydroxyspirol indanl .3 pyrrolidin1-l '-yl) butyrophenone lRS,3RS-Spiro[indanl ,3 -pyrrolidin ]-3-ol is reacted n accordance with the process described in Example l(A) or l(B). A solution of hydrochloric acid in ethaiol is added to the crude title compound, and the hyirochloride of the title compound is crystallized by the rddition of some ether. M.P. 2l02l l".

The starting material may be obtained as follows:

a. Spirolindan-l,3'-pyrrolidinl-3,5'-dione is reduced 11 a manner analogous to that described in Example l(g) with sodium borohydride. The resulting 3- \ydr0xyspiro[indan-l,3'-pyrrolidin]-5-one is a mix vure of diastereoisomers having a M.P. of l2()l30, :ontains about 50 72 of the ]RS,3RS isomer and about 50 of the lRS,3SR isomer. 30 g of the crude mixture ire extracted thrice with 100 cc amounts of chloroform at the boil. lRS,3RS-3-hydroxyspiro[indan-1,3- pyrrolidin]-5'-one, having a M.P. of l50-l52, is obtained as extraction residue and is further reduced with lithium aluminium hydride in a manner analogous to that described in Example 3(h).

1RS.3SR-3-Hydroxyspiro[indanl ,3-pyrrolidin 5'-one, having a M.P. of l2()l23, crystallizes from the chloroform solution after the addition of ether.

EXAMPLE l7: lRS,3SR-p-Fluoro-4-( 3-hydroxyspiro[indanl ,3 pyrrolidin]- l '-yl) butyrophenone lRS,3SR-Spiro[ indanl ,3 '-pyrrolidin ]-3-ol is reacted in a manner analogous to that described in Example 1 (A) or 1 (B). The hydrogen fumarate of the title compound has a M.P. of [83 (from ethanol/ether).

The starting material may be obtained by reducing the lRS,3SR-3-hydroxyspiro[ indan-l ,3 '-pyrrolidin 5'-one, obtained in Example 16 (a), in a manner analogous to that described in Example 3 (h).

EXAMPLE l8: 4-( 3-Acetoxyspiro[ indanl ,3 '-pyrrolidin ]-l -yl )-pfluorobutyrophenone EXAMPLE l9: p-Fluoro-4-(S-methylcarbamoyloxyspiro[indan-1 ,3 pyrrolidin1- l -yl) butyrophenone 9.0 g of p-fluoro-4-(3-hydroxyspiro[indan-1,3-

pyrrolidinl-l '-yl) butyrophenone and 2.0 g of methyl isocyanate are dissolved in 50 cc of methylene chloride. After allowing the reaction solution to stand at room temperature for 20 hours, it is concentrated by evaporation, and the resulting oil is converted into the hydrogen fumarate. After recrystallization from ethanol/ether, the hydrogen fumarate of the title compound has a M.P. of l67l69.

EXAMPLE 20: p-Fluoro-4-(5-methyl-3-propionyloxyspiro[ indan-l ,3 pyrrolidin1-l -yl) butyrophenone p-Fluoro-4-( 3-hydroxy-5-methylspiro[ indanl ,3 pyrrolidinl-l '-yl) butyrophenone is reacted with propionic acid anhydride in a manner analogous to that described in Example IS. The hydrogen fumarate of the title compound has a M.P. of l53l55 (from ethanol/ether).

EXAMPLE 2| 4-( S-Chloro-3-methylcarbamoylspirol indanl ,3 pyrrolidinll '-yl )-p-fluorobutyrophenone 4-( S-Chloro-3-hydroxyspirol indan-l ,3 '-pyrrolidin 1 '-yl )-p-fluorobutyrophenonc is reacted with methyl isocyanate in chloroform in a manner analogous to that described in Example [9. Reaction time 24 hours at the boil. The hydrogen fumarate of the title compound has a MP. of lll53 (from ethanol/ether).

EXAMPLE 22: 2-[ 3( 3-Hydroxyspirol indanl ,3 '-pyrrolidin ]-l yl )propyl ]-2-( p-fluorophenyl )-l ,3-dioxolane [5 g of spirolindan-l,3'-pyrrolidin]-3-ol are dissolved in 200 cc of dimethyl formamide and heated to 100 for 20 hours with IS g of sodium carbonate and 23 g of 2-(3-chloropropyl)-2-(p-fluorophenyl)l,3- dioxolane. Filtration is subsequently effected, the filter residue is washed with l 50 cc of chloroform and the organic phases are concentrated. The title compound obtained as yellow oil is purified by chromatography. Thin layer chromatogram: Rf value 0.600 (adsorbent: silica gel, eluant: benzene/ethanol/ammonia :4:02).

The hydrogen fumarate of p-fluoro-4-( 3- hydroxyspiro[ indanl ,3 '-pyrrolidin]-l '-ol) butyrophenone, obtained by hydrolysis of the ketal group of the title compound, has a M.P. of l74l76 (from ethanol/ether).

Hydrolysis is effected by dissolving the title compound in 300 cc of chloroform and stirring at room temperature for 1V2 hours with 250 cc of 2 N hydrochloric acid. The solution is then made alkaline with caustic soda solution, the chloroform phase is separated, and the crude pfl uoro-4-( 3-hydroxyspiro[ indanl,3'-pyrrolidin]-l'-yl) butyrophenone, obtained after concentrating the chloroform phase, is converted into the hydrogen fumarate with fumaric acid.

In analogous manner to that described in the preceding Example, 2-[ 3-( 3-hydroxyspirolindan-l ,3 pyrrolidin l-l '-yl )propyl ]-2-( pfluorophenyl l .3- dioxane may be produced.

The following compounds of formula lg may be produced in a manner analogous to that described in Ex ample 22 and may be characterized by the melting point of the hydrogen fumarate of the butyrophenone derivative obtained by hydrolysis of the compound:

R jgju n I H Rf value (thin layer 3-Acetoxyspiro[indan-l,3'-pyrrolidine] is reacted in a manner analogous to that described in Example 1 (B). The crude title compound obtained as an oil is converted into its hydrogen fumarate with fumaric acid and is recrystallized from ethanol/ether. M.P. l54l56.

The starting material may be obtained as follows:

a. 56.0 g of l'-benzyl-3-hydroxyspiro[indan-l ,3- pyrrolidine] are stirred at room temperature with l20 cc of pyridine and 120 cc of acetic anhydride for 20 hours. The mixture is then poured on ice, is made alkaline with 2 N caustic soda solution and is extracted thrice with 250 cc amounts of ether. The ether phase is washed with water, dried over sodium sulphate and concentrated by evaporation. l '-Benzyl-3- acetoxyspiro[indan-l,3'-pyrrolidine] is obtained as light yellow oil, which is used for the next reaction without purification.

b. 30.0 g of the product obtained above are dissolved in 300 cc of ethanol, 3.0 g of palladium charcoal are added, and hydrogenation is elTected at and a hydrogen pressure of 76 atmospheres for l2 hours. Filtration is effected, the ethanol is distilled off, and 3- acetoxyspiro[indan-l ,3-pyrrolidine] is obtained as residue in the form of an almost colourless oil. which is used as such for the next reaction.

EXAMPLE 35: p-Fluoro-4-( 3-methylcarbamoyloxyspiro[ indanl .3 pyrrolidin l -yl) butyrophenone 3-Methylcarbamoyloxyspiro[ indanl ,3 -pyrrolidine] is reacted in a manner analogous to that described in Example I (B), and the title compound is converted into its hydrogen fumarate. M.P. l67l69 (from ethanol/ether).

The starting material may be obtained as follows:

A. 56.0 g of 1'-benzyl-3-hydroxyspiro[indan-l,3'- pryrrolidine] and 10.0 g of methyl isocyanate are dissolved in -pyrrolidine]500 cc of methylene chloride. After allowing the reaction solution to stand at room temperature for 20 hours, the solvent is distilled off. The resulting oily l -benzyl-3- methylcarbamoyloxyspirolindan-l ,3 '-pyrrolidine] is used for the next reaction without purification.

B. 250 g of the product obtained above are dissolved in 300 cc of ethanol, and hydrogenation is efi'ected in the presence of 3.0 g of palladium charcoal at 50 and Example R R chromatogrum on MP. of the hydrogen fumarate No. silica gel. eluant: of the butyrophenone derivative hcnzene/ethanol/ammonia l5 4 0.2)

23 5Cl H 0.700 148- 49 (ethanol/ether) 24 4CH; O H 0.6 l0 l52- l 54 (ethanol/ether) 2S 6CH O H (1.645 163- (ethanol/ether) 26 4-Cl H 0. 570 PIS- (ethanol/ether) 27 6Cl H 0.630 l65 l 67 (ethanol/ether) 28 6CH H 0.590 I 8 1-183 (ethanol/ether) 29 5CH ,0 H 0.680 l 13-1 15 (ethanol/ether) 30 5 F H 0.6) 143-145 (ethanol/ether) 3| 5-CH H 0.530 163- 64 (ethanol/ether) 32 4-Cl 5 Cl 0.790 l9(l 93 (ethanol/ether) 33 5Cl 7-Cl (1.675 l49-l 52 (ethanol/ether) EXAMPLE 34: 4-( 3-Acetoxyspirol indanl ,3 -pyrrolidin l -yl )-pfluorobutyrophenone 5 6 a hydrogen pressure of 51 atmospheres for 15 hours.

The catalyst is then filtered off, the ethanol is removed by distillation, and 3-methylcarbamoyloxyspirolindan- 23 l,3 '-pyrrolidine] is obtained as residue. The oily prodict is used for the next reaction without further purifi- :ation.

EXAMPLE 36: l RS.3RS )-4-(S-chloro-3-hydroxyspiro-[indane-l .3 pyrrolidin ]-l '-yl )-p-fluorobutyrophenone 15 g of -chlorospiro[indane-l .3-pyrrolidin]-3-ol mixture of diastereoisomers of 50 7c of the lRS,3SR md 50 of the lRS.3RS isomer) are dissolved in 200 re of dimethyl formamide and heated to 100 for 6 lours together with 18 g of sodium carbonate and 23 of 2-( 3-chloropropyl )-2-( p-fluorophenyl )-l ,3- lioxolane. Filtration is subsequently effected, the filter esidue is washed with chloroform and the organic hase is concentrated. The resulting yellow oil is taken p in 300 cc of chloroform and stirred at room temperture for 1 hour with 250 cc of 2 N hydrochloric acid. he reaction mixture is subsequently made alkaline Iith caustic soda solution while cooling, is extracted rith chloroform and the chloroform phase is concen- 'ated. The crude title compound is obtained together ith the lRS,3-SR isomer as brown oil. After adding a Jlution of hydrogen chloride in ethanol. the lRS,3S'R )rm crystallizes alone. The hydrochloride form of the ure title compound has a MP. of 203206 after rerystallization from ethanol/ether.

ln analogous manner Example 36 is repeated using 3-chloropropyl )-2-(p-fluorophenyl l ,3-dioxane 'hereupon the intermediate compound obtained is the tle compound in l.3-clioxane form instead of in 1.3 ioxolane form. The intemiediates may be purified if esired in conventional manner.

. EXAMPLE 37: lRS.3SR )-4-( 5-chloro-3-hydroxyspiro-[ indanel .3 pyrrolidin l '-yl )-p-fl uorobutyrophenone g of (lRS,3SR)-5chlorospiro[indane-1,3- yrrolidinl-B-ol in 200 cc of dimethyl formamide are :ated to 100 for 6 hours together with 18 g of sodium irbonate and 23 g of 2-(3-chloropropyl)-2-(p- .iorophenyU-l .3-dioxolane. Filtration is subsequently Tected, the filter residue is washed with chloroform 1d the organic phase is concentrated. The resulting :llow oil is taken up in 300 cc of chloroform and irred at room temperature for 1 hour with 250 cc of N hydrochloric acid. The reaction mixture is subseiently made alkaline with caustic soda solution while ioling, the chloroform phase is separated and concen ated. After the addition of a solution of fumaric acid alcohol, the hydrogen fumarate form of the title Impound crystallizes. M.P. lS4l56 from hanol/ether. The starting material may be obtained as follows: a. 210 g of 5-chlorospiroIindane-l.3'-pyrrolidine]- 5-dione are dissolved in 2.5 liters of methanol. and solution of g of sodium horohydride in 250 cc of itcr and 5 cc of caustic soda solution is added at room Tipcrature at such a rate that the temperature in the action vessel does not exceed The solution is rred at room temperature for 2 hours, is then poured ice and extracted several times with chloroform. 10 S-chloro-3-hydroxyspiro[indanc-1.3 '-pyrrolidin -one, obtained after concentrating the chloroform lution by evaporation. is a mixture of diastereiomers. having a MP. of l55-l80. and containing proximately equal parts of the lRS.3SR and the lRS,3RS isomer. Pure lRS,3SR)-5-chloro-3- hydroxyspirolindanel .3 -pyrrolidin]-5 '-one. having a M.P. of 21 3-2l6. may be obtained by extracting repeatedly with chloroform and subsequently recrystallizing twice from methanol.

b. A solution of 25 g of lRS.3SR)-5-chloro-3- hydroxyspiro[indane-l,3-pyrrolidin]-5-one in 100 cc of tetrahydrofuran is added dropwise to a suspension of 8 g of lithium aluminium hydride in 200 cc of tetrahydrofuran and 200 cc of ether. The mixture is boiled at reflux for 20 hours, is then carefully decomposed with 75 cc of water. filtration is effected and the organic phase is concentrated. The lRS,3SR)-5- chlorospiro[ indanel .3 -pyrrolidin ]-3-ol, obtained as yellow oil. is used for the next reaction without further purification.

EXAMPLE 38: lRS,3SR )-p-fluoro-4-( 3-hydroxy-5- methylspiro[ indanel .3 '-pyrrolidin l yl)butyrophenone EXAMPLE 39: 1 R83 RS )-p-fluoro-4-( 3-hydroxy-5 methylspiro[ indane-l .3 '-pyrrolidin ]-1 yl )butyrophenone Crude lRS.3RS)-5-methylspiro[indane-1,3- pyrrolidin]-3-ol (containing approximately 20 of the lRS,3SR isomer) is reacted in a manner analogous to that described in Example 36. Hydrochloric acid in ethanol is added to the crude title compound, containing impurities of the lRS,3SR isomer, whereby the hydrochloric form of the sterically uniform title compound crystallizes after the addition of some ether. M.P. l37l39.

EXAMPLE 40: lRS.3RS)-4-( 3-acetoxyspirol indane-l .3 '-pyrrolidin l '-yl )-p-fluorobutyrophenone 7.5 g of (lRS.3RS)-p-fluoro-4-( 3- hydroxyspirol indanel .3 -pyrrolidin ]-l yl)butyrophenone arc stirred at room temperature for 20 hours together with 15 cc of pyridine and I5 cc of acetic anhydride. The reaction mixture is then poured on ice. is made alkaline with 2 N caustic soda solution and is extracted thrice with 100 cc amounts of ether. The crude title compound obtained as oily residue after concentrating the ether phase by evaporation. is converted into the hydrogen fumarate form, which is recrystallized from ethanol/ether. MP. of the hydrogen fumarate form of the title compound: l68l 70.

The following esters are produced in a manner analogous to that described in Example 40. by reaction of the corresponding p-fluoro-4-( 3-hydroxyspirolindanel.3-pyrrolidin]-l -yl )butyrophenone with a corresponding acid anhydride.

EXAMPLE 41 lRS,3 RS )-p-fluoro-4-( 3-propionyloxyspiro-l indanel.3 '-pyrrolidin l '-yl )butyrophenone M.P. of the hydrogen fumarate form: lll 52.

EXAMPLE 42: (lRS.3RS)-4-[ 3-( 2,2- dimethylpropionyloxyspirol indanel ,3 -pyrrolidin l yl ]-p-fluorobutyrophenone M.P. of the hydrogen fumarate form: l47-l48.

EXAMPLE 43: IRS,3RS )-p-fluoro-( 5-methyl-3- propionyloxyspirolindanel ,3 -pyrrolidin ]-l yl )butyrophenone M.P. of the hydrogen fumarate form: l80l 81.

EXAMPLE 44: lRS,3SR )-p-fluoro-( 5-mcthyl-3- propionyloxyspirolindane-1,3 -pyrrolidin ]-l yl )butyrophenone M.P. of the hydrogen fumarate form: l68l69.

EXAMPLE 4s:

wherein R is hydrogen. alkyl of l to 3 carbon atoms,

fluorine, chlorine. bromine or methoxy,

R is hydrogen, alkyl of l to 3 carbon atoms, chlorine or methoxy, or

R. and R are ortho one to another and together form a methylene dioxy group,

R is hydroxy, alkylcarboxy of 2 to 5 carbon atoms or monoalkylcarbamoyloxy of 2 to 5 carbon atoms, and

A is carbonyl. l,3-dioxolan-2-ylidene or l,3-dioxan- 2-ylidene,

in free base or pharmaceutically acceptable acid addition salt form thereof.

2. A compound of claim 1, wherein R and R of formula l are each hydrogen.

3. A compound of claim 1. wherein one of R and R of formula I is other than hydrogen and is in the 5- position of the indan nucleus.

4. A compound of claim 1, wherein R of formula I is methylcarboxy or methylcarbamoyloxy.

5. A compound of claim 1 in IRS, 3R5 racemic form.

6. A compound of claim I in IRS, 3SR racemic form.

7. A compound of claim 1, which is p-fluoro-4-(3- hydroxyspiro[indanl ,3-pyrrolidin]-l '-yl) butyrophenone.

8. A compound of claim 1, which is p-fluoro-4 (3- hydr0xy-6-methoxyspiro[ indanl ,3 -pyrrolidin ]-l '-yl) butyrophenone.

9. A compound of claim 1, which is 4-(6-chloro-3- hydroxyspiro[indan- 1 ,3 '-pyrrolidin ]-l '-yl)-pfluorobutyrophenone.

10. A compound of claim 1, which is 4-(4-chloro-3- hydroxyspiro[ indanl ,3-pyrrolidin ]-1 '-yl )-pfluorobutyrophenone.

11. A compound of claim 1, which is 4-(5-chloro-3- hydroxyspiro[indanl ,3 '-pyrrolidin]- l '-yl )-pfluorobutyrophenone.

12. A compound of claim I, which is p-fluoro-4-(3- hydroxy-4-methoxyspiro[ indan-l ,3 '-pyrrolidin ]-l '-yl butyrophenone.

13. A compound of claim 1, which is p-fluoro-4-(3- hydroxy-6-methylspiro[indan-l ,3 -pyrrolidin l '-yl butyrophenone.

14. A compound of claim 1, which is p-fluoro-4-(5- fluoro-3-hydroxyspiro[indan-1,3'-pyrrolidin l-l '-yl butyrophenone.

15. A compound of claim 1. which is p-fluoro-4-(3- hydroxy-5-methoxyspiro[ indan-l ,3 '-pyrrolidin ]-l -y] butyrophenone.

16. A compound of claim 1, which is p-fluoro-4-(3- hydroxy-S-methylspriol indanl ,3 '-pyrrolidin l -yl butyrophenone.

17. A compound of claim 1, which is 4-(5,7-dichloro- 3-hydroxyspiro[ indanl ,3 '-pyrrolidin ]-l '-yl )-pfluorobutyrophenone.

18. A compound of claim 1, which is 4-( 4,5-dichloro- 3-hydroxyspiro[indan- 1,3 '-pyrrolidin]- l '-yl )-pfluorobutyrophenone.

19. A compound of claim I, which is 4-(3-hydroxy- 5,6-dimethoxyspiro[ indan-l ,3 -pyrrolidin ]-l '-yl )-pfluorobutyrophenone.

20. A compound of claim 1, which is 4-( 3-hydroxy-5- isopropylspirolindanl ,3 '-pyrrolidin ]-1 '-yl )-pfluorobutyrophenone.

21. A compound of claim 1, which is 4-(3-hydroxy- 5,7-dimethylspiro[indanl ,3 -pyrrolidin]- l '-yl)-pfluorobutyrophenone.

22. A compound of claim 1, which is 4-(3- acetoxyspiro[ indanl ,3 '-pyrrolidin ]-l '-y[ )-pfluorobutyrophenone.

23. A compound of claim 1, which is p-fluoro-4-( 3- methylcarbamoyloxyspiro[indan-l ,3 -pyrrolidin l' yl) butyrophenone.

24. A compound of claim 1, which is p-fluoro-4-(5- methyl-3-propionyloxyspirol indan-l ,3 '-pyrrolidin l'-yl) butyrophenone.

25. A compound of claim 1, which is 4-(5-chloro-3- methylcarbamoylspiro[indan-l ,3 -pyrrolidin ]-l '-yl )-pfluorobutyrophenone.

26. A compound of claim 1. which is p-fluoro-4-(3- propionyloxyspiro[ indanl ,3 '-pyrrolidin l '-yl )-pfluorobutyrophenone.

66. A compound of claim 64. wherein R is hydrogen. boxy.

67. A compound of claim 66, wherein R is hydrogen, 7!. A compound of claim 64, wherein R, and R are alkyl, chlorine or methoxy. independently hydrogen, chlorine, alkyl or methoxy.

68. A compound of claim 67, wherein R is hydroxy, 72. A compound of claim 1, wherein R and R are alkylcarboxy or monoalkylcarbamoyloxy. 5 independently hydrogen, alkyl, chlorine, fluorine, or

69. A compound of claim 64, wherein R;, is hydroxy. methoxy and A is carbonyl or 1,3-dioxolan-2-ylidene.

70. A compound of claim 64, wherein R is alkylcar- 

1. A COMPOUND OF THE FORMULA:
 2. A compound of claim 1, wherein R1 and R2 of formula I are each hydrogen.
 3. A compound of claim 1, wherein one of R1 and R2 of formula I is other than hydrogen and is in the 5- position of the indan nucleus.
 4. A compound of claim 1, wherein R3 of formula I is methylcarboxy or methylcarbamoyloxy.
 5. A compound of claim 1 in 1RS, 3RS racemic form.
 6. A compound of claim 1 in 1RS, 3SR racemic form.
 7. A compound of claim 1, which is p-fluoro-4-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl) butyrophenone.
 8. A compound of claim 1, which is p-fluoro-4-(3-hydroxy-6-methoxyspiro(indan-1,3''-pyrrolidin)-1''-yl) butyrophenone.
 9. A compound of claim 1, which is 4-(6-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 10. A compound of claim 1, which is 4-(4-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 11. A compound of claim 1, which is 4-(5-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 12. A compound of claim 1, which is p-fluoro-4-(3-hydroxy-4-methoxyspiro(indan-1,3''-pyrrolidin)-1''-yl) -butyrophenone.
 13. A compound of claim 1, which is p-fluoro-4-(3-hydroxy-6-methylspiro(indan-1,3''-pyrrolidin)-1''-yl) -butyrophenone.
 14. A compound of claim 1, which is p-fluoro-4-(5-fluoro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl) -butyrophenone.
 15. A compound of claim 1, which is p-fluoro-4-(3-hydroxy-5-methoxyspiro(indan-1,3''-pyrrolidin)-1''-yl) -butyrophenone.
 16. A compound of claim 1, which is p-fluoro-4-(3-hydroxy-5-methylsprio(indan-1,3''-pyrrolidin)-1''-yl) -butyrophenone.
 17. A compound of claim 1, which is 4-(5,7-dichloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 18. A compound of claim 1, which is 4-(4,5-dichloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 19. A compound of claim 1, which is 4-(3-hydroxy-5,6-dimethoxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 20. A compound of claim 1, which is 4-(3-hydroxy-5-isopropylspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 21. A compound of claim 1, which is 4-(3-hydroxy-5,7-dimethylspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 22. A compound of claim 1, which is 4-(3-acetoxyspiro(indan-1, 3''-pyrrolidin)-1''-yl)-p-fluorobutyrophenone.
 23. A compound of claim 1, which is p-fluoro-4-(3-methylcarbamoyloxyspiro(indan-1,3''-pyrrolidin)-1''-yl) butyrophenone.
 24. A compound of claim 1, which is p-fluoro-4-(5-methyl-3-propionyloxyspiro(indan-1,3''-pyrrolidin)-1''-yl) butyrophenone.
 25. A compound of claim 1, which is 4-(5-chloro-3-methylcarbamoylspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 26. A compound of claim 1, which is p-fluoro-4-(3-propionyloxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 27. A compound of claim 1, which is 4-(3-(2,2-dimethyl-propionyloxyspiro(indan-1,3''-pyrrolidin)-1''-yl))-p -fluorobutyrophenone.
 28. A compound of claim 1, which is 2-(3-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p-fluorophenyl)-1,3-dioxolane.
 29. A compound of claim 1, which is 2-(3-(5-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 30. A compound of claim 1, which is 2-(3-(3-hydroxy-4-methoxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 31. A compound of claim 1, which is 2-(3-(3-hydroxy-6-methoxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 32. A compound of claim 1, which is 2-(3-(4-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 33. A compound of claim 1, which is 2-(3-(6-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 34. A compound of claim 1, which is 2-(3-(3-hydroxy-6-methylspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 35. A compound of claim 1, which is 2-(3-(3-hydroxy-5-methoxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 36. A compound of claim 1, which is 2-(3-(5-fluoro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 37. A compound of claim 1, which is 2-(3-(3-hydroxy-5-methylspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 38. A compound of claim 1, which is 2-(3-(4,5-dichloro-3-hyroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 39. A compound of claim 1, which is 2-(3-(5,7-dichloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 40. A compound of claim 1, which is 2-(3-(5,6-dimethoxy-3-hydroxysprio(indan-1,3''-pyrrolidin)-1''-yl)prOpyl)-2-(p-fluorophenyl)-1,3-dioxolane.
 41. A compound of claim 1, which is 2-(3-(3-hydroxy-5-isopropylspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 42. A compound of claim 1, which is 2-(3-(5,7-dimethyl-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 43. A compound of claim 1, which is 2-(3-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p-fluorophenyl)-1,3-dioxane.
 44. A compound of claim 1, which is 2-(3-(5-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxane.
 45. A compound of claim 1, which is 4-(3-hydroxy-5,6-methylenedioxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p-fluoro -butyrophenone.
 46. The compound of claim 1, which is (1RS,3RS)-p-fluoro-4-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 47. The compound of claim 1, which is (1RS,3SR)-p-fluoro-4-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 48. The compound of claim 1, which is (1RS,3RS)-4-(5-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 49. The compound of claim 1, which is (1RS,3SR)-4-(5-chloro-3-hydroxyspiro(indane-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 50. The compound of claim 1, which is (1RS,3SR)-p-fluoro-4-(3-hydroxy-5-methylspiro(indane-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 51. The compound of claim 1, which is (1RS,3RS)-p-fluoro-4-(3-hydroxy-5-methylspiro(indane-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 52. The compound of claim 1, which is (1RS,3RS)-4-(3-acetoxyspiro(indane-1,3''-pyrrolidin)-1''-yl)-p -fluorobutyrophenone.
 53. The compound of claim 1, which is (1RS,3RS)-p-fluoro-4-(3-propionyloxyspiro(indane-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 54. The compound of claim 1, which is (1RS,3RS)-4-(3-(2,2-dimethylpropionyloxyspiro(indane-1,3''-pyrrolidin)-1'' -yl))-p-fluorobutyrophenone.
 55. The compound of claim 1, which is (1RS,3RS)-p-fluoro-(5-methyl-3-propionyloxyspiro(indane-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 56. The compound of claim 1, which is (1RS,3SR)-p-fluoro-(5-methyl-3-propionyloxyspiro(indan-1,3''-pyrrolidin)-1'' -yl)butyrophenone.
 57. The compound of claim 1, which is (1RS,3RS)-4-(3-hydroxy-5, 7-dimethylspiro(indan-1,3''-pyrrolidin)-1''-yl)-p-fluorobutyrophenone.
 58. The compound of claim 1, which is (1RS,3SR)-4-(3-hydroxy-5, 7-dimethylspiro(indan-1,3''-pyrrolidin)-1''-yl)-p-fluorobutyrophenone.
 59. The compound of claim 1, which is (1RS,3RS)-2-(3-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 60. The compound of claim 1, which is (1RS,3SR)-2-(3-(3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p -fluorophenyl)-1,3-dioxolane.
 61. The compound of claim 1, which is (1RS,3SR)-2-(3-(5-chloro-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl)-2-(p-fluorophenyl)-1,3-dioxolane.
 62. The compound of claim 1, which is (1RS,3SR)-2-(3-(5-methyl-3-hydroxyspiro(indan-1,3''-pyrrolidin)-1''-yl)propyl -2-(p-fluorophenyl)-1,3-dioxolane.
 63. A compound of claim 1, which is an individual (1RS, 3RS) or (1RS, 3SR) compound of formula
 64. A compound of claim 1, wherein A is carbonyl.
 65. A compound of claim 1, wherein A is 1,3-dioxolan-2-ylidene, or 1,3-dioxan-2-ylidene.
 66. A compound of claim 64, wherein R2 is hydrogen.
 67. A compound of claim 66, wherein R1 is hydrogen, alkyl, chlorine or methoxy.
 68. A compound of claim 67, wherein R3 is hydroxy, alkylcarboxy or monoalkylcarbamoyloxy.
 69. A compound of claim 64, wherein R3 is hydroxy.
 70. A compound of claim 64, wherein R3 is alkylcarboxy.
 71. A compound of claim 64, wherein R1 and R2 are independently hydrogen, chlorine, alkyl or methoxy.
 72. A compound of claim 1, wherein R1 and R2 are independently hydrogen, alkyl, chlorine, fluorine, or methoxy and A is carbonyl or 1,3-dioxolan-2-ylidene. 